NASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free XGN Stock Alerts $1.56 +0.02 (+1.30%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$1.46▼$1.5850-Day Range$1.42▼$2.3052-Week Range$1.33▼$3.92Volume47,620 shsAverage Volume60,299 shsMarket Capitalization$26.89 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exagen alerts: Email Address Exagen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside284.6% Upside$6.00 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.41Based on 7 Articles This WeekInsider TradingSelling Shares$24,417 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.48) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.66 out of 5 starsMedical Sector78th out of 939 stocksMedical Laboratories Industry3rd out of 19 stocks 3.5 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Exagen has a forecasted upside of 284.6% from its current price of $1.56.Amount of Analyst CoverageExagen has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.07% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently increased by 20.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 2.4 News and Social Media Coverage News SentimentExagen has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Exagen this week, compared to 1 article on an average week.Search Interest1 people have searched for XGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,417.00 in company stock.Percentage Held by Insiders36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.48) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Exagen Stock (NASDAQ:XGN)Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More XGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Stock News HeadlinesMarch 16, 2024 | insidertrades.comInsider Selling: Exagen Inc. (NASDAQ:XGN) CFO Sells 12,784 Shares of StockMarch 22, 2024 | americanbankingnews.comBrokers Set Expectations for Exagen Inc.'s Q1 2024 Earnings (NASDAQ:XGN)March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 21, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual ReportMarch 21, 2024 | americanbankingnews.comWilliam Blair Weighs in on Exagen Inc.'s Q1 2025 Earnings (NASDAQ:XGN)March 20, 2024 | seekingalpha.comExagen Inc. (XGN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exagen on Strong Financials and Strategic Growth InitiativesMarch 20, 2024 | finance.yahoo.comExagen Full Year 2023 Earnings: Beats ExpectationsMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 19, 2024 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | markets.businessinsider.comExagen’s Strong Q4 Performance and Positive Outlook Justify Buy RatingMarch 18, 2024 | markets.businessinsider.comHere's what to expect from Exagen's earningsMarch 18, 2024 | msn.comExagen reports Q4 resultsMarch 18, 2024 | investorplace.comXGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023March 18, 2024 | msn.comAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksMarch 18, 2024 | globenewswire.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 ResultsMarch 18, 2024 | finance.yahoo.comXGN Apr 2024 2.500 putMarch 8, 2024 | finance.yahoo.comExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumMarch 8, 2024 | globenewswire.comExagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumMarch 7, 2024 | globenewswire.comExagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024February 6, 2024 | finance.yahoo.comDespite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain StockJanuary 30, 2024 | finance.yahoo.comExagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceJanuary 8, 2024 | msn.comExagen reaffirms FY23 revenue of at least $50MJanuary 7, 2024 | finance.yahoo.comExagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms GuidanceDecember 30, 2023 | benzinga.comExagen Stock (NASDAQ:XGN) Dividends: History, Yield and DatesDecember 20, 2023 | msn.comExagen submits plans for new solar farm in WiltshireNovember 17, 2023 | msn.comExagen files for a $150M mixed shelf offeringSee More Headlines Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today3/27/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees199Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,690,000.00 Net Margins-45.08% Pretax Margin-45.02% Return on Equity-80.28% Return on Assets-36.27% Debt Debt-to-Equity Ratio0.85 Current Ratio4.02 Quick Ratio4.02 Sales & Book Value Annual Sales$52.55 million Price / Sales0.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.17Miscellaneous Outstanding Shares17,240,000Free Float10,893,000Market Cap$26.89 million OptionableOptionable Beta1.23 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Tina S. Nova Ph.D. (Age 70)Executive Chairman of Board Comp: $65kMr. John Aballi (Age 39)CEO, President & Director Comp: $558.84kMr. Kamal Adawi M.S. (Age 45)MBA, CFO & Corporate Secretary Comp: $483.28kRyan DouglasInvestors Relations OfficerMr. John Wegener (Age 55)Senior Vice President of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardDr. Michael I. Nerenberg M.D. (Age 69)Chief Medical Officer More ExecutivesKey CompetitorsDermTechNASDAQ:DMTKAkuminNASDAQ:AKUMQCentogeneNASDAQ:CNTGPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCView All CompetitorsInsiders & InstitutionsKamal AdawiSold 12,784 sharesTotal: $24,417.44 ($1.91/share)Nantahala Capital Management LLCSold 9,645 shares on 2/15/2024Ownership: 0.570%Citadel Advisors LLCBought 200 shares on 2/15/2024Ownership: 0.000%RTW Investments LPBought 12,170 shares on 2/14/2024Ownership: 8.825%Wasatch Advisors LPSold 5,965 shares on 2/14/2024Ownership: 4.987%View All Insider TransactionsView All Institutional Transactions XGN Stock Analysis - Frequently Asked Questions Should I buy or sell Exagen stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price target for 2024? 2 brokers have issued 12-month target prices for Exagen's shares. Their XGN share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 284.6% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2024? Exagen's stock was trading at $1.99 at the beginning of 2024. Since then, XGN shares have decreased by 21.6% and is now trading at $1.56. View the best growth stocks for 2024 here. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) issued its earnings results on Monday, March, 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.02. The company had revenue of $13.77 million for the quarter, compared to the consensus estimate of $11.43 million. Exagen had a negative trailing twelve-month return on equity of 80.28% and a negative net margin of 45.08%. During the same quarter in the prior year, the company earned ($0.58) earnings per share. What guidance has Exagen issued on next quarter's earnings? Exagen updated its FY 2024 earnings guidance on Monday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.0 million-$54.0 million, compared to the consensus revenue estimate of $54.1 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? Exagen (XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. Who are Exagen's major shareholders? Exagen's stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (8.82%), Wasatch Advisors LP (4.99%), Stonepine Capital Management LLC (3.93%), Perkins Capital Management Inc. (2.98%), Nantahala Capital Management LLC (0.57%) and Dimensional Fund Advisors LP (0.21%). Insiders that own company stock include James L L Tullis, John Aballi, Kamal Adawi, Mark Hazeltine and Wendy S Johnson. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XGN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.